Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for … – The Herald | HeraldOnline.com

Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for
The Herald | HeraldOnline.com
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product
Rigel Pharma (RIGL) Starts Clinical Studies For Asthma, Discoid LupusiStockAnalyst
Rigel Begins Trial With Advanced Proprietary Therapeutic Product CandidatesNASDAQ

all 13 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.